Fierce Pharma’s Spotlight on CV6 and Northern Ireland Life Sciences
CV6 Therapeutics is featured in a sponsored Fierce Pharma article examining investment in Northern Ireland’s life and health sciences sector.
Published in February 2023, the article explores the company’s move from California to Belfast and its $9.2 million funding announcement to support CV6-168’s progression into first-in-human clinical trials. It also highlights the region’s research expertise, university partnerships and support for life sciences companies.
Source: Fierce Pharma. Originally published February 27, 2023. Sponsored content.
More News
View all
UTV Reports on CV6-168’s Progress Toward First Human Trials
UTV highlights plans to advance CV6’s Belfast-developed cancer drug into its first human trial, alongside the investment and research support behind its development.
CV6 CEO Presents at ‘Agreement 25: Cancer Knows no Borders’
The focus of the world was on Belfast as global political leader’s past, and present arrived in Belfast to mark the 25th anniversary of the Belfast/Good Friday Agreement.